vatalanib
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Brain and Central Nervous System Tumors
Conditions
Brain and Central Nervous System Tumors, Sarcoma
Trial Timeline
May 1, 2006 → Jul 1, 2013
NCT ID
NCT00348790About vatalanib
vatalanib is a phase 2 stage product being developed by Novartis for Brain and Central Nervous System Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT00348790. Target conditions include Brain and Central Nervous System Tumors, Sarcoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00348790 | Phase 2 | Completed |
| NCT00590343 | Phase 2 | Completed |
| NCT00056459 | Phase 3 | Completed |
| NCT00056446 | Phase 3 | Completed |
Competing Products
20 competing products in Brain and Central Nervous System Tumors
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Abemaciclib + Endocrine therapy | Eli Lilly | Phase 1/2 | 41 |
| Duloxetine + Sugar pill | Eli Lilly | Phase 2 | 52 |
| Neurosteroid enantiomer | Oragenics | Phase 2 | 44 |
| Patritumab deruxtecan | Daiichi Sankyo | Phase 2 | 52 |
| filgrastim + exatecan mesylate | Daiichi Sankyo | Phase 1 | 33 |
| Eribulin Mesylate | Eisai | Phase 1 | 33 |
| Pembrolizumab + Lenvatinib | Eisai | Phase 2 | 52 |
| Palonosetron (Aloxi) and Dexamethasone | Eisai | Phase 2 | 52 |
| GLIADEL | Eisai | Phase 2 | 52 |
| Nivolumab + Temozolomide | Ono Pharmaceutical | Phase 3 | 77 |
| Nivolumab + Temozolomide | Ono Pharmaceutical | Phase 3 | 77 |
| Prexasertib + Cyclophosphamide + Gemcitabine + filgrastim + peg-filgrastim | Eli Lilly | Phase 1 | 33 |
| abemaciclib + abemaciclib | Eli Lilly | Phase 2 | 52 |
| JNJ-17299425 | Johnson & Johnson | Phase 2 | 52 |
| ABT-888 | AbbVie | Phase 1 | 33 |
| Veliparib + Placebo | AbbVie | Phase 2 | 52 |
| Iressa (Gefitinib) | AstraZeneca | Phase 2 | 52 |
| Trastuzumab deruxtecan | AstraZeneca | Phase 2 | 52 |
| Exenatide | AstraZeneca | Approved | 85 |
| AZD5213 | AstraZeneca | Phase 1 | 33 |